CCA
LGND icon

Conestoga Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Conestoga Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-706,606
Closed -$57.8M – 148
2021
Q2 		$57.8M Sell
706,606
-88,291
-11% -$7.34M 0.84% 46
2021
Q1 		$75.6M Sell
794,897
-353,556
-31% -$33.4M 1.14% 40
2020
Q4 		$71.3M Buy
1,148,453
+11,288
+1% +$644K 1.14% 42
2020
Q3 		$67.6M Buy
1,137,165
+58,718
+5% +$4.01M 1.36% 37
2020
Q2 		$75.2M Buy
1,078,447
+38,736
+4% +$2.46M 1.64% 32
2020
Q1 		$47.2M Buy
1,039,711
+46,407
+5% +$2.63M 1.38% 39
2019
Q4 		$64.6M Sell
993,304
-20,904
-2% -$1.4M 1.56% 36
2019
Q3 		$63M Sell
1,014,208
-6,420
-0.6% -$403K 1.61% 31
2019
Q2 		$72.7M Buy
1,020,628
+25,155
+3% +$1.85M 1.82% 25
2019
Q1 		$78.1M Buy
995,473
+215,080
+28% +$16.3M 2.17% 18
2018
Q4 		$66.1M Sell
780,393
-127,262
-14% -$13.6M 2.1% 22
2018
Q3 		$155M Buy
907,655
+103,119
+13% +$15.5M 3.97% 1
2018
Q2 		$104M Buy
804,536
+50,276
+7% +$5.61M 3.35% 1
2018
Q1 		$77.7M Sell
754,260
-30,937
-4% -$3.06M 2.98% 3
2017
Q4 		$67.1M Buy
785,197
+90,898
+13% +$7.88M 2.58% 14
2017
Q3 		$59M Buy
694,299
+75,751
+12% +$6M 2.61% 10
2017
Q2 		$46.8M Buy
618,548
+40,227
+7% +$2.81M 2.44% 14
2017
Q1 		$38.2M Buy
578,321
+31,663
+6% +$2.08M 2.31% 17
2016
Q4 		$34.7M Buy
546,658
+2,492
+0.5% +$157K 2.31% 16
2016
Q3 		$34.6M Buy
544,166
+40,428
+8% +$2.97M 2.37% 16
2016
Q2 		$37.5M Sell
503,738
-158,881
-24% -$11.8M 2.77% 11
2016
Q1 		$44.3M Buy
662,619
+203,901
+44% +$12.4M 2.99% 10
2015
Q4 		$31M Sell
458,718
-36,208
-7% -$2.24M 2.51% 14
2015
Q3 		$26.4M Sell
494,926
-18,260
-4% -$1.11M 2.12% 25
2015
Q2 		$32.3M Sell
513,186
-8,544
-2% -$466K 2.24% 19
2015
Q1 		$25.1M Sell
521,730
-7,366
-1% -$282K 1.72% 31
2014
Q4 		$17.6M Buy
529,096
+59,326
+13% +$1.93M 1.22% 37
2014
Q3 		$13.8M Buy
469,770
+78,691
+20% +$2.61M 1.01% 43
2014
Q2 		$15.2M Buy
+391,079
New +$15.9M 1.02% 44

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Conestoga Capital Advisors's LGND Position: Q3 2021 in Review

Conestoga Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2021, closing a stake of 706,606 shares — an estimated $57.8M sold.

Conestoga Capital Advisors first reported a position in LGND in Q2 2014 and held it in 29 quarters. The position peaked at $155M in Q3 2018. 207 funds tracked by Wall St. Rank hold LGND as of Q3 2021.

  • Conestoga Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Conestoga Capital Advisors sold 706,606 Ligand Pharmaceuticals shares in Q3 2021, an estimated $57.8M.
  • Conestoga Capital Advisors first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 29 quarters.
  • Conestoga Capital Advisors's Ligand Pharmaceuticals position peaked at $155M in Q3 2018.
  • 207 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2021.

Based on Conestoga Capital Advisors's 13F filing for Q3 2021, filed 22 Oct 2021.